在四个多发性硬化学术中心的多发性硬化治疗克拉德里宾片的现实世界经验
Devon S Conway1, Jacqueline A Nicholas2, Nicolas R Thompson3
1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Multiple sclerosis and related disorders
|January 19, 2025
概括
实践数据显示,克拉德里宾片 (CladT) 改善了多发性硬化症 (MS) 患者的步行速度,并表明与其他疾病修饰疗法 (DMT) 相比,放射效果延迟. 比以前研究的更广泛的MS群体中,CladT是有效的.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉迪布林片 (CladT) 是一种成熟的多发性硬化症 (MS) 疾病修饰疗法 (DMT).
- 需要真实世界的数据来了解CladT在多样化的MS群体中的有效性和患者轨迹.
- 与其他DMT进行比较分析对于明智的临床决策至关重要.
研究的目的:
- 评估在现实环境中使用CladT治疗多发性硬化症 (PwMS) 患者的临床和放射性结果.
- 使用倾向匹配,比较CladT与其他DMT的有效性.
- 在24个月内评估神经性能和MRI指标.
主要方法:
- 在4个中心对117名PwMS接受CladT治疗的回顾性分析.
- 使用电子神经性能测试 (zWST,zMDT,zPST),PDDS和NeuroQoL的结果.
- 使用通用估计方程进行纵向分析和倾向匹配,以比较其他DMT的有效性.
主要成果:
- 在CladT上的PwMS显示了步行速度 (zWST) 和稳定的患者确定的疾病步骤 (PDDS) 的显著改善.
- 在6个月和18个月后,CladT治疗与加多增强病变的几率降低有关.
- 对比分析表明,CladT与其他DMT的zWST和疲劳得分更好,X光学损伤结果在24个月后相似.
结论:
- 现实世界CladT在MS中的使用涉及比临床试验更长的疾病持续时间的老年患者.
- 在这个更广泛的人群中,CladT表现良好,改善了步行速度和潜在的延迟放射性益处.
- 相对有效性表明CladT的结果有利,特别是在疲劳和步行速度方面.
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...